Tracking CRP Blood Levels in Gynecological Cancers Treated With Immunotherapy
Observes C-reactive protein blood levels in adults with advanced gynecological cancers receiving immunotherapy.
Plain-language title generated from the registry record
Registry title: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
Key facts
- Where
- Tübingen, GermanySee the site
Where in Germany
- Department of Women's HealthTübingen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Tuebingen
- Trial code
- NCT05914974
- Record updated
- 10 February 2026
- Original description
ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).Read full original descriptionShow less
ICK-Gyn: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).
Inclusion: women ≥ 18 years of age; histologically proven metastatic gynecological malignancies irrespective of therapy line; patients with advanced or metastatic gynecological malignancies must fulfill treatment requirements for ICI therapy in the experimental group; planned ICI therapy in combination with palliative chemotherapy in the experimental group; patients with advanced or metastatic gynecological malignancies that undergo chemotherapy without ICIs in the first therapy line in the control group; written informed consent into ICK-Gyn.
Exclusion: missing indication for ICI therapy in the experimental group; any ICI therapy before inclusion into the trial; patients with advanced or metastatic endometrial or cervical cancer in the second or higher therapy line without indication to ICI therapy; inadequate general condition (not fit for chemotherapy); pregnant or lactating patients.